Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Methylprednisolone Acetate | |
| Synonyms |
Methylprednisolone Acetate ReadySharp MethylPrednisolone 80 Depo-Medrate 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-Acetate Depo-Medrol Depo-Medrone METHYLPREDNISOLONE ACETATE Methylprednisolone acetate D-Med |
|
| Definitions |
The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C48003 |
|
| CAS_Registry |
53-36-1
|
|
| CHEBI_ID |
CHEBI:6889
|
|
| Chemical_Formula |
C24H32O6
|
|
| code |
C48003
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 |
|
| Contributing_Source |
FDA GDC
|
|
| DEFINITION |
The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.
|
|
| FDA_UNII_Code |
43502P7F0P
|
|
| FULL_SYN |
Methylprednisolone Acetate ReadySharp MethylPrednisolone 80 Depo-Medrate 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-Acetate Depo-Medrol Depo-Medrone METHYLPREDNISOLONE ACETATE Methylprednisolone acetate D-Med
|
|
| Has_Free_Acid_Or_Base_Form | ||
| Is_Value_For_GDC_Property | ||
| label |
Methylprednisolone Acetate
|
|
| Legacy Concept Name |
Methylprednisolone_Acetate
|
|
| Maps_To |
Methylprednisolone Acetate
|
|
| NCI_Drug_Dictionary_ID |
41528
|
|
| NSC Number |
48985
|
|
| PDQ_Closed_Trial_Search_ID |
41528
|
|
| PDQ_Open_Trial_Search_ID |
41528
|
|
| Preferred_Name |
Methylprednisolone Acetate
|
|
| prefixIRI |
Thesaurus:C48003
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0600901
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |